Skip to main content

Codiak BioSciences, Inc. (CDAK)

NASDAQ: CDAK · Delayed Price · USD
17.20 -1.65 (-8.75%)
Sep 24, 2021 4:00 PM EDT - Market closed
Market Cap393.25M
Revenue (ttm)16.68M
Net Income (ttm)-89.36M
Shares Out22.12M
EPS (ttm)-5.79
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume78,012
Open18.76
Previous Close18.85
Day's Range17.00 - 18.85
52-Week Range7.90 - 37.85
Betan/a
AnalystsStrong Buy
Price Target36.67 (+113.2%)
Est. Earnings DateNov 4, 2021

About CDAK

Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12, an exosome therapeutic candidates, for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; exoASO-NLRP3 for multiple sclerosis, neuropathy, and neurod...

IndustryBiotechnology
IPO DateOct 14, 2020
CEODouglas Williams
Employees105
Stock ExchangeNASDAQ
Ticker SymbolCDAK
Full Company Profile

Financial Performance

In 2020, CDAK's revenue was $2.92 million, an increase of 651.29% compared to the previous year's $388,000. Losses were -$91.67 million, 17.6% more than in 2019.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for CDAK stock is "Strong Buy." The 12-month stock price forecast is 36.67, which is an increase of 113.20% from the latest price.

Price Target
$36.67
(113.20% upside)
Analyst Consensus: Strong Buy

News

Codiak BioSciences Appoints Lini Pandite, MBChB, MBA to Board of Directors

CAMBRIDGE, Mass., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutic...

1 month ago - GlobeNewsWire

Codiak BioSciences Reports Second Quarter 2021 Financial Results and Operational Progress

– Initial safety and PK/PD data from Phase 1/2 study of exoSTING™ now expected in the fourth quarter of 2021 –

1 month ago - GlobeNewsWire

Codiak BioSciences to Present at the Virtual William Blair Biotech Focus Conference 2021

CAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutic...

2 months ago - GlobeNewsWire

Codiak BioSciences Announces the Transition of Benny Sorensen, M.D., Ph.D. to Scientific Advisory Board Member and Cl...

– Dr. Sorensen to become CEO of a start-up hemostasis and thrombosis company – – Dr. Sorensen to become CEO of a start-up hemostasis and thrombosis company –

2 months ago - GlobeNewsWire

Codiak BioSciences to Present at the Goldman Sachs 42nd Annual Global Healthcare Virtual Conference

CAMBRIDGE, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutic...

3 months ago - GlobeNewsWire

Codiak BioSciences Appoints Anne-Virginie Eggimann, M.Sc., to Board of Directors

– Executive leader with deep regulatory experience bringing innovative biopharmaceutical products from early development to market approval – – Executive leader with deep regulatory experience bringing ...

4 months ago - GlobeNewsWire

Codiak BioSciences Reports First Quarter 2021 Financial Results and Operational Progress

– Key clinical data from first in-human studies of engineered exosome therapeutic candidates, exoIL-12™ and exoSTING™, expected this year –

4 months ago - GlobeNewsWire

Codiak to Present Preclinical Data Demonstrating Broad Potential Applications for Engineered Exosomes at the American...

– engEx™ Platform and in vitro and in vivo findings support utility across multiple therapeutic areas – – engEx™ Platform and in vitro and in vivo findings support utility across multiple therapeutic ar...

4 months ago - GlobeNewsWire

Data from Codiak's exoSTING™ Preclinical Development Program for the Treatment of Solid Tumors Published in the Natur...

– exoSTING has demonstrated enhanced potency, preferential activation of antigen presenting cells, and systemic anti-tumor immunity in vivo –

5 months ago - GlobeNewsWire

Codiak Presents Data at AACR 2021 Demonstrating Potential of Engineered Exosomes to Enhance the Therapeutic Index of ...

– exoASO™-STAT6 mediated genetic reprogramming of tumor associated macrophages results in potent single-agent anti-tumor activity in multiple preclinical models; IND submission planned for H2 2021 –

5 months ago - GlobeNewsWire

Codiak BioSciences Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Progress

– First human proof-of-concept data from exoIL-12™ program confirmed desired product profile and enabled dose selection for further evaluation in patients –

6 months ago - GlobeNewsWire

Codiak to Present Data from Two Novel Engineered Exosome Therapeutic Candidate Programs at the American Association f...

– Healthy volunteer clinical data for exoIL-12 accepted as a late-breaking abstract –

6 months ago - GlobeNewsWire

Cellarity Raises $123 Million in Series B Funding to Pioneer a New Approach to Drug Discovery, Treating Disease at th...

CAMBRIDGE, Mass., Feb. 25, 2021 /PRNewswire/ -- Cellarity, a life sciences company founded by Flagship Pioneering to develop a new method of drug discovery targeting the cell, announced today that it ra...

7 months ago - PRNewsWire

Codiak Announces Closing of $66.4 Million Public Offering, Including Full Exercise of Underwriters' Option

CAMBRIDGE, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK) (“Codiak”), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based ...

7 months ago - GlobeNewsWire

Codiak Announces Pricing of $57.8 Million Public Offering of Common Stock

CAMBRIDGE, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK) (“Codiak”), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based ...

7 months ago - GlobeNewsWire

Codiak Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK) (“Codiak”), a clinical-stage company focused on pioneering the development of exosome-based therapeutics as a ...

7 months ago - GlobeNewsWire

Codiak Reports Additional Positive Phase 1 Results for exoIL-12™ Confirming Local Pharmacology and Dose Selection for...

– Pharmacodynamic results confirm localized exoIL-12 pharmacologic activity

7 months ago - GlobeNewsWire

Codiak's Versatile engEx™ Platform for Engineered Exosomes Published in the Journal Molecular Therapy

– New publication details the characterization of novel scaffold proteins that can enable engineered exosomes with defined therapeutic properties –

8 months ago - GlobeNewsWire

Codiak Reports Positive Initial Phase 1 Results for exoIL-12™ Demonstrating Tolerability and Absence of Systemic IL-1...

– exoIL-12 resulted in no local or systemic treatment-related adverse events –

8 months ago - GlobeNewsWire

Codiak BioSciences to Present at the Evercore ISI 3rd Annual HealthCONx Conference

CAMBRIDGE, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage company focused on pioneering the development of exosome-based therapeutics as a new class o...

10 months ago - GlobeNewsWire

Codiak BioSciences Reports Third Quarter 2020 Financial Results and Operational Progress

– Human clinical testing now underway with Codiak's first two candidates, exoIL-12™ and exoSTING™ –

10 months ago - GlobeNewsWire

Codiak Presents Preclinical Data at SITC 2020 Demonstrating Potential of engEx™ Engineered Exosomes to Stimulate Targ...

– exoIL-12™ demonstrates tissue-retained pharmacology, enhanced anti-tumor activity, potent M1 myeloid recruitment, and superior T cell responses in vivo –

10 months ago - GlobeNewsWire

U.S. IPO Weekly Recap: Solar Technology Shines In A 9-IPO Week

Nine IPOs and five SPACs went public this past week, and one IPO postponed.

11 months ago - Seeking Alpha

Codiak Announces Pricing of Initial Public Offering

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Codiak BioSciences, Inc. (“Codiak”), a clinical-stage company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today an...

11 months ago - Business Wire